Lovastatin Reduces Stemness via Epigenetic Reprograming
of BMP2 and GATA2 in Human Endometrium
The stem cell theory in the endometriosis provides an advanced avenue of
targeting these cells as a novel therapy to eliminate endometriosis. In this regard, studies
showed that lovastatin alters the cells from a stem-like state to more differentiated condition and reduces stemness. The aim of this study was to investigate whether lovastatin
treatment could influence expression and methylation patterns of genes regulating differentiation of endometrial mesenchymal stem cells (eMSCs) such as
Materials and Methods
In this experimental investigation, MSCs were isolated from endometrial and endometriotic tissues and treated with lovastatin and decitabin.
To investigate the osteogenic and adipogenic differentiation of eMSCs treated with the different
concentration of lovastatin and decitabin,
In the present study, treatment with lovastatin increased expression of
These findings indicated that lovastatin treatment could increase the differentiation of eMSCs toward osteogenic and adiogenic lineages, while it decreased expression of eMSCs markers and subsequently reduced the stemness.